There are a lot of ASX shares out there for investors to choose from.
To narrow things down, let's take a look at three popular shares and see what Morgans is saying about them.
Are they buys, holds, or sells? Let's find out:
Image source: Getty Images
Northern Star Resources Ltd (ASX: NST)
This gold miner has been given a hold rating and $26.00 price target by Morgans. While it is a fan of Northern Star, it hasn't been impressed with its recent performance.
And with potentially more challenges to come, it thinks investors are better off sitting on the sidelines for the time being. The broker said:
NST has revised FY26 guidance lower after another soft sales quarter, cutting the midpoint ~8% to 1,650koz (from 1,775koz). The downgrade reflects ongoing operational challenges across all hubs, including grade, throughput and utilisation constraints. This marks the second guidance miss in as many years. While we remain constructive on NST's long-term growth pathway, we are adopting a more cautious (previously bullish) short-to-midterm production outlook, maintained until delivery consistency improves.
We now forecast FY26 sales of 1,589koz (-9%), marginally below updated guidance (1,600–1,700koz). We lift our AISC to A$2,770/oz, reducing forecast EBITDA and EPS by 16% and 22% respectively. Rating revised to HOLD, price target A$26.00ps (previously A$27.41ps). The downgrade partly offset by our higher spot scenario of US$3,500/oz (from US$3,250/oz).
Pro Medicus Ltd (ASX: PME)
This health imaging technology company's shares have been hammered due to the tech selloff.
Morgans thinks that this could be an opportunity to start accumulating shares and sees fair value at $290.00.
Commenting on the ASX share, the broker said:
PME's share price has continued to decline since our last update, despite stable fundamentals and a consistent outlook. This decrease appears to be due to a broader market shift away from high-growth stocks, as there have been no major new contracts or company-specific changes for PME since our previous report. Business quality remains solid with high margins, long-term contracted revenues, and a growing contract book which underpins the demand and safety in the financial profile over the coming years.
No change to valuation (A$290 p/s) and longstanding positive outlook, just a better entry point. Upgrade to an ACCUMULATE recommendation, with the view that current prices represent a reasonable opportunity for partial positions, noting ongoing volatility in the name could still yet present further downside.
Web Travel Group Ltd (ASX: WEB)
Another ASX share that Morgans thinks investors should accumulate is WebBeds owner Web Travel. It has a price target of $5.20 on its shares, which is around 11% higher than current levels.
Morgans was pleased with its recent trading update and highlights its undemanding valuation. It said:
While WEB reported strong top line growth, this did not translate into strong NPATA growth (fell 7.4% on the pcp). However, cashflow was stronger than expected and the balance sheet is in a strong net cash position. Pleasingly, WEB's trading update was stronger than expected and top line growth has accelerated. FY26 guidance was slightly stronger than expected and we have upgraded our forecasts.
WEB's outlook comments for FY27 were also upbeat. With 19% [now 11%] upside to A$5.20 price target and trading on undemanding fundamentals, we upgrade to an Accumulate recommendation.
